Login
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc.

whitehawktx.com

What Do They Do?

Develops cancer drug candidates for people with lung, ovarian and other cancers.

How Do They Make Money?

Whitehawk sold FYARRO to specialty distributors and a specialty pharmacy; product sales were counted when those buyers obtained the drug. It later sold the FYARRO business.

FY2025 revenue

Who Are Their Customers?

Whitehawk sold FYARRO to specialty distributors and a specialty pharmacy; government and other entities bought through those channels at discounted prices.

Customers above 10% of revenue, FY2025
of revenue from two customers (37%, 60%)
FY2024: 98% from two customers

Do Revenues Turn Into Profits?

No. It lost $20.6M in FY2025.

Operating income, FY2025
−1601% of revenue
▼ −70% (Loss) vs FY2024 (−$67.5M, −260%)
Net income, FY2025
−288% of revenue
▲ +68% (Loss) vs FY2024 (−$63.7M, −245%)
Free cash flow, FY2025
−1371% of revenue
▼ −60% (Loss) vs FY2024 (−$61.2M, −236%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −20% (Loss)
vs −$17.7M in Q3 FY2025
  • May 21, 2026 Adds an option for additional ADC programs The agreement gives Whitehawk global rights and program control for new programs.

Growing. Revenue grew 6.4x in 4 years, from $1.1M in FY2021 to $7.1M in FY2025, about 59% a year.

From FYARRO to ADC candidates Earlier, Whitehawk focused on developing and commercializing FYARRO, an albumin-bound sirolimus treatment for cancers involving mTOR pathway alterations. The latest report focuses on developing licensed antibody-drug conjugates for cancers, rather than commercializing FYARRO.

Who Do They Compete With?

Competes with AbbVie, Daiichi Sankyo, Day One Biopharmaceuticals, Eli Lilly, Genmab, GlaxoSmithKline, Gilead, Kelun, Mersana, Sanofi, Roche, Pfizer, Zymeworks, Ideaya, and Biocytogen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support